Funding the next breakthrough in brain cancer research. Together.
Despite being first identified in the scientific literature in the 1920s, there are only four FDA-approved drugs to treat Glioblastoma (GBM). Four in 100 years. For Glioblastoma (GBM), the five-year relative survival rate is only 7.2% and median survival is only 8 months.
These devastating statistics attest to the underfunded and under-researched nature of brain cancer treatments – particularly treatments for high-grade gliomas.
Our mission is to fund innovative research on aggressive brain cancers to give patients a shot at a longer life. Our vision is a world where a GBM diagnosis is treatable and curable.
We work directly with medical research partners at the Preston Robert Tisch Brain Tumor Center at Duke to fund innovative research for clinical trials and life saving treatments.
For more information on the Knox Martin Foundation, visit knoxmartinfoundation.org/our-story